Stage IV Salivary Gland Cancer Completed Phase 2 Trials for Cetuximab (DB00002)

Also known as: Salivary gland cancer stage IV / Metastatic salivary gland cancer / Malignant salivary gland cancer stage IV

IndicationStatusPhase
DBCOND0028780 (Stage IV Salivary Gland Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01316757Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerTreatment